Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM)
about
Management of lymphangioleiomyomatosisClinical features, epidemiology, and therapy of lymphangioleiomyomatosisUterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs.Folliculin controls lung alveolar enlargement and epithelial cell survival through E-cadherin, LKB1, and AMPK.Retrospective review of combined sirolimus and simvastatin therapy in lymphangioleiomyomatosisSustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.Anti-EGFR antibody reduces lung nodules by inhibition of EGFR-pathway in a model of lymphangioleiomyomatosis.Inhibitory effects of Stemona tuberosa on lung inflammation in a subacute cigarette smoke-induced mouse modelTumor suppressors TSC1 and TSC2 differentially modulate actin cytoskeleton and motility of mouse embryonic fibroblasts.Wild type mesenchymal cells contribute to the lung pathology of lymphangioleiomyomatosisSurfactant dysfunction and lung inflammation in the female mouse model of lymphangioleiomyomatosisPharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosisTherapeutic Strategies for Treatment of Pulmonary Lymphangioleiomyomatosis (LAM)Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM)Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials.Could simvastatin be considered as a potential therapy for chronic lung diseases? A debate on the pros and cons.Diagnosis and treatment of cystic lung disease.Tsc2 disruption in mesenchymal progenitors results in tumors with vascular anomalies overexpressing Lgals3.New insights into the pathophysiology of the tuberous sclerosis complex: Crosstalk of mTOR- and hippo-YAP pathways in cell growth.Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
P2860
Q28084725-A772CD55-6AAC-49B5-A79C-99571F264C74Q28084975-9F3F6401-C960-4AF2-B800-90AC5E469407Q30411083-9201F363-6BA3-42A3-B5E4-07F2272E2DB9Q30578909-C8C50A7A-A950-478A-978E-082FF9F7C5E5Q34840298-3A25819A-A2A5-4E11-8B13-A8DACF01A8AFQ35044713-5D660DA8-361C-404C-9626-1FF3ACB4EED2Q35074335-9A0EB3E2-C404-4440-8212-4D0E69E06A6FQ35191277-C6CA8D85-6259-4F43-BFA6-EBF1B6C3EFE7Q35381119-49FC4314-EEDF-4143-964C-2A5FB856BB66Q35610828-5275875D-77DE-4322-8651-4815B8AF7868Q36049475-1B2B7B26-93F5-48D3-B0C9-7D763C8501B0Q36382124-45E8D6EB-49F0-4A00-A27C-8050DAA546D8Q36462100-4BCAE538-A28D-4B71-93DB-F940B483A509Q36636671-90AEF67E-D5B9-43FA-B748-C02BC28BEB37Q37596461-2F817D9E-6F96-47E9-8E8A-FA97386FDE74Q38372196-3C23E7EA-A1CF-41D1-9648-F42D96C9F7EAQ38841393-73A57C65-29F7-4747-8FD5-B3349600812EQ39164137-2D7D2C17-0BA8-4451-BA45-2375FB22FDB3Q40984224-0935B123-7041-4A9A-B9BB-783B622AEC44Q41597933-56A0FD58-463F-4F87-8907-FFCC940E0B19Q41614453-F794A0EF-BE41-4D2E-B501-0D7162DF4271Q42595723-D626529B-0080-46D8-B5BB-D940FB7DA298Q51779283-14C0C964-B7FE-47DE-9A19-51CE7B5C6276
P2860
Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM)
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Prevention of alveolar destruc ...... lymphangioleiomyomatosis (LAM)
@ast
Prevention of alveolar destruc ...... lymphangioleiomyomatosis (LAM)
@en
type
label
Prevention of alveolar destruc ...... lymphangioleiomyomatosis (LAM)
@ast
Prevention of alveolar destruc ...... lymphangioleiomyomatosis (LAM)
@en
prefLabel
Prevention of alveolar destruc ...... lymphangioleiomyomatosis (LAM)
@ast
Prevention of alveolar destruc ...... lymphangioleiomyomatosis (LAM)
@en
P2093
P2860
P1476
Prevention of alveolar destruc ...... lymphangioleiomyomatosis (LAM)
@en
P2093
Blerina Ducka
Dmitry A Goncharov
Elena A Goncharova
Irene Khavin
Melane Fehrenbach
Mervyn J Merrilees
Steven M Albelda
Thomas V Colby
Vera P Krymskaya
P2860
P304
P356
10.1126/SCITRANSLMED.3003840
P407
P577
2012-10-01T00:00:00Z